MX2022012083A - Moleculas de union de antigeno multiespecificas y usos de las mismas. - Google Patents

Moleculas de union de antigeno multiespecificas y usos de las mismas.

Info

Publication number
MX2022012083A
MX2022012083A MX2022012083A MX2022012083A MX2022012083A MX 2022012083 A MX2022012083 A MX 2022012083A MX 2022012083 A MX2022012083 A MX 2022012083A MX 2022012083 A MX2022012083 A MX 2022012083A MX 2022012083 A MX2022012083 A MX 2022012083A
Authority
MX
Mexico
Prior art keywords
binding
antigen
target molecule
multispecific antigen
effector protein
Prior art date
Application number
MX2022012083A
Other languages
English (en)
Inventor
Nicholas J Papadopoulos
Aris N Economides
Katherine Diana Cygnar
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022012083A publication Critical patent/MX2022012083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee moléculas de unión de antígeno multiespecíficas y usos de las mismas. Las moléculas de unión de antígeno multiespecíficas comprenden un primer dominio de unión de antígeno que se une específicamente a una molécula objetivo, y un segundo dominio de unión de antígeno que se une específicamente a una proteína efectora de internamiento. Las moléculas de unión de antígeno multiespecíficas de la presente invención, en algunas modalidades, pueden ser anticuerpos biespecíficos que son capaces de unirse tanto a una molécula objetivo como a una proteína efectora de internamiento. En algunas modalidades de la invención, la unión simultánea de la molécula objetivo y la proteína efectora de internamiento efectuada por la molécula de unión de antígeno multiespecífica de la presente invención, atenúa la actividad de la molécula objetivo a un mayor grado que la unión de la molécula objetivo sola. En otras modalidades de la invención, la molécula objetivo es un antígeno asociado con tumor, y la unión simultánea del antígeno asociado con tumor y la proteína efectora de internamiento de la presente invención ocasiona o facilita la destrucción dirigida de células de tumor.
MX2022012083A 2012-03-14 2014-09-12 Moleculas de union de antigeno multiespecificas y usos de las mismas. MX2022012083A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610494P 2012-03-14 2012-03-14
US201261721831P 2012-11-02 2012-11-02
US201361751286P 2013-01-11 2013-01-11

Publications (1)

Publication Number Publication Date
MX2022012083A true MX2022012083A (es) 2022-10-21

Family

ID=48014317

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014011052A MX361875B (es) 2012-03-14 2013-03-13 Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
MX2022012083A MX2022012083A (es) 2012-03-14 2014-09-12 Moleculas de union de antigeno multiespecificas y usos de las mismas.
MX2018010776A MX2018010776A (es) 2012-03-14 2014-09-12 Moleculas de union de antigeno multiespecificas y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014011052A MX361875B (es) 2012-03-14 2013-03-13 Moléculas de unión de antígeno multiespecifícas y usos de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018010776A MX2018010776A (es) 2012-03-14 2014-09-12 Moleculas de union de antigeno multiespecificas y usos de las mismas.

Country Status (19)

Country Link
US (2) US20130243775A1 (es)
EP (2) EP3421488A3 (es)
JP (4) JP6883944B2 (es)
KR (3) KR20140135233A (es)
CN (2) CN114133454A (es)
AU (2) AU2013232266A1 (es)
BR (1) BR112014022692A8 (es)
CA (1) CA2867265C (es)
DK (1) DK2825553T3 (es)
EA (1) EA036225B1 (es)
ES (1) ES2687974T3 (es)
IL (1) IL234460B (es)
MX (3) MX361875B (es)
MY (1) MY171761A (es)
NZ (1) NZ631565A (es)
PL (1) PL2825553T3 (es)
SG (3) SG10201709018QA (es)
WO (1) WO2013138400A1 (es)
ZA (1) ZA201406671B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107488228A (zh) 2008-04-11 2017-12-19 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
DK2825553T3 (en) * 2012-03-14 2018-09-24 Regeneron Pharma : Multispecific antigen binding molecules and applications thereof
MX2019001355A (es) 2012-05-10 2023-01-17 Bioatla Llc Anticuerpos monoclonales multiespecíficos.
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2014159595A2 (en) 2013-03-14 2014-10-02 Regeneron Pharmaceuticals, Inc. Human antibodies to nav1.7
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
US20170058045A1 (en) * 2014-02-21 2017-03-02 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
EP3277725B1 (en) 2015-03-30 2020-11-25 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
MX2017017117A (es) 2015-07-06 2018-03-06 Regeneron Pharma Moleculas multiespecificas de union a antigenos y usos de estas.
PL3386534T3 (pl) * 2015-12-08 2021-03-08 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby internalizacji enzymów
WO2017134197A1 (en) * 2016-02-05 2017-08-10 Genmab A/S Multispecific antigen-binding molecule with improved internalization characteristics
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2017190079A1 (en) * 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2018107109A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
WO2018139623A1 (en) * 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018152326A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
MA50546A (fr) 2017-06-07 2020-09-16 Regeneron Pharma Compositions et méthodes pour l'internalisation d'enzymes
SG11201911886PA (en) 2017-06-27 2020-01-30 Regeneron Pharma Non-human animals comprising a humanized asgr1 locus
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP2021523147A (ja) * 2018-05-09 2021-09-02 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗ｍｓｒ１抗体及びその使用方法
AU2019269685A1 (en) * 2018-05-17 2020-12-03 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
JP2021527103A (ja) * 2018-06-14 2021-10-11 バイオアトラ インコーポレイテッド 多重特異性抗体構造体
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US20220023434A1 (en) * 2018-12-19 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
CA3125316A1 (en) 2018-12-28 2020-07-02 Kyowa Kirin Co., Ltd. Bispecific antibody binding to tfr
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
CN114127113A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与钙网蛋白结合的多功能分子及其用途
SG11202109033XA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CA3130508A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
US20220185903A1 (en) * 2019-03-04 2022-06-16 Nantong Yichen Biopharma. Co. Ltd. Novel bispecific binding molecule and drug conjugate thereof
CA3142735A1 (en) * 2019-06-06 2020-12-10 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
EP4003534A1 (en) * 2019-07-30 2022-06-01 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics Inc CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2021333779A1 (en) 2020-08-26 2023-04-13 Marengo Therapeutics, Inc. Methods of detecting TRBC1 or TRBC2
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
KR20230074144A (ko) 2020-08-26 2023-05-26 마렝고 테라퓨틱스, 인크. NKp30에 결합하는 항체 분자 및 이의 용도
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
US20230338477A1 (en) 2022-02-02 2023-10-26 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
WO2024026488A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified transferrin receptor locus

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US5229272A (en) 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
US5156965A (en) 1983-11-29 1992-10-20 Igen, Inc. Catalytic antibodies
US5126258A (en) 1984-09-07 1992-06-30 Scripps Clinic And Research Foundation Molecules with antibody combining sites that exhibit catalytic properties
US5030717A (en) 1986-09-17 1991-07-09 Scripps Clinic And Research Foundation Antibodies which catalyze hydrolysis of ester bonds
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5858728A (en) 1991-03-13 1999-01-12 Common Services Agency Monoclonal antibody against LPS core
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
JP3822231B2 (ja) 1993-04-23 2006-09-13 イゲン，インコーポレーテッド 一級アミドを加水分解する触媒抗体およびそのような抗体を誘発する方法
US5602021A (en) 1994-12-29 1997-02-11 Catalytic Antibodies, Inc. Method for generating proteolytic enzymes specific against a selected peptide sequence
JP2001503253A (ja) 1996-10-17 2001-03-13 イムノメディクス，インコーポレイテッド 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク
JP2002511857A (ja) 1997-06-11 2002-04-16 ザ スクール オブ ファーマシー ユニヴァーシティ オブ ロンドン 抗体−酵素複合体をプロドラッグと組合せて含む薬学的組成物
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
AU2226799A (en) 1998-01-15 1999-08-02 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US6703488B1 (en) * 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US6855804B2 (en) 1998-03-23 2005-02-15 Board Of Regents, The University Of Texas System Covalently reactive transition state analogs and methods of use thereof
US6235714B1 (en) 1998-03-23 2001-05-22 Sudhir Paul Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
AU1203000A (en) 1998-10-09 2000-05-01 President And Fellows Of Harvard College Targeted proteolysis by recruitment to ubiquitin protein ligases
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
KR100816958B1 (ko) * 1999-07-30 2008-03-26 메다렉스, 인코포레이티드 항-Ｆｃ 수용체 결합제를 포함하는 치료 화합물
EP1231944A2 (en) * 1999-11-15 2002-08-21 University Of Southern California Targeted delivery of therapeutic and diagnostic moieties
DE10034607A1 (de) 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
AU2001295041A1 (en) 2000-09-08 2002-03-22 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20060210474A1 (en) 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1439857B1 (en) 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
EP1633865B1 (en) 2003-06-18 2011-09-28 Bayer Pharma Aktiengesellschaft New biological entities and the use thereof
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
UA93653C2 (ru) * 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7371539B2 (en) 2003-12-03 2008-05-13 President And Fellows Of Harvard College Targeted polypeptide degradation
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US8518403B2 (en) 2004-07-16 2013-08-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US9127293B2 (en) 2006-07-26 2015-09-08 The University Of Chicago Receptor-mediated delivery: compositions and methods
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
SI2511301T1 (en) 2006-08-04 2018-05-31 MedImmune Limited, Human antibodies to ERBB 2
WO2008051326A2 (en) * 2006-08-21 2008-05-02 President And Fellows Of Harvard College Identification of contactins and l1- cams as ligands for the amyloid precursor protein
WO2008150485A2 (en) 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US8420620B2 (en) * 2008-01-24 2013-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Induced internalization of surface receptors
EP2274008B1 (en) * 2008-03-27 2014-02-26 ZymoGenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
EP2342231A1 (en) 2008-09-26 2011-07-13 Roche Glycart AG Bispecific anti-egfr/anti-igf-1r antibodies
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
EP2241576A1 (en) 2009-04-17 2010-10-20 Trion Pharma Gmbh Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
CA2798562A1 (en) * 2010-05-07 2011-11-10 Ranju Ralhan Methods and compositions for the diagnosis and treatment of thyroid cancer
EP2576621B1 (en) * 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
WO2012136519A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
CA2832387A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
CA2828662A1 (en) 2011-04-20 2012-10-26 Roche Glycart Ag Method and constructs for the ph dependent passage of the blood-brain-barrier
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
DK2825553T3 (en) * 2012-03-14 2018-09-24 Regeneron Pharma : Multispecific antigen binding molecules and applications thereof
US20150125449A1 (en) 2012-05-10 2015-05-07 Zymeworks Inc. Single-Arm Monovalent Antibody Constructs and Uses Thereof
LT2890712T (lt) 2012-08-29 2019-07-25 F. Hoffmann-La Roche Ag Šaudyklinis nešiklis per kraujo ir smegenų barjerą
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UY35460A (es) 2013-03-15 2014-10-31 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US9738717B2 (en) 2013-05-15 2017-08-22 The Translational Genomics Research Institute Hybridoma clones, monoclonal antibodies, and methods of use
CN104211814A (zh) 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
CN106573074B (zh) 2014-06-02 2022-04-12 里珍纳龙药品有限公司 生物活性分子偶联物、试剂和制备方法及其治疗用途
MX2017017117A (es) 2015-07-06 2018-03-06 Regeneron Pharma Moleculas multiespecificas de union a antigenos y usos de estas.
PL3386534T3 (pl) 2015-12-08 2021-03-08 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby internalizacji enzymów
WO2017134197A1 (en) 2016-02-05 2017-08-10 Genmab A/S Multispecific antigen-binding molecule with improved internalization characteristics
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
IL266917B2 (en) 2016-11-29 2023-10-01 Regeneron Pharma Conjugates of a drug and an antibody to the human prolactin receptor (PRLR) and their use in the combined treatment of PRLR-positive breast cancer
MA50546A (fr) 2017-06-07 2020-09-16 Regeneron Pharma Compositions et méthodes pour l'internalisation d'enzymes
EP3652205A1 (en) 2017-07-10 2020-05-20 Bayer Pharma Aktiengesellschaft Prolactin receptor antibody for male and female pattern hair loss
MX2020011487A (es) 2018-04-30 2020-12-07 Regeneron Pharma Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.

Also Published As

Publication number Publication date
AU2017251854A1 (en) 2017-11-16
CA2867265C (en) 2024-01-02
US20130243775A1 (en) 2013-09-19
EA201491686A1 (ru) 2014-12-30
EP3421488A2 (en) 2019-01-02
US20190309061A1 (en) 2019-10-10
EA036225B1 (ru) 2020-10-15
MX2014011052A (es) 2015-03-09
JP2019089806A (ja) 2019-06-13
US20210115132A9 (en) 2021-04-22
SG10201704846VA (en) 2017-07-28
BR112014022692A8 (pt) 2021-07-20
MY171761A (en) 2019-10-28
NZ631565A (en) 2016-07-29
MX2018010776A (es) 2020-09-02
BR112014022692A2 (pt) 2017-06-20
KR102283200B1 (ko) 2021-07-29
SG10201709018QA (en) 2017-11-29
AU2013232266A1 (en) 2014-10-02
SG11201405468QA (en) 2014-10-30
WO2013138400A1 (en) 2013-09-19
EP3421488A3 (en) 2019-04-17
KR20140135233A (ko) 2014-11-25
CN104302664A (zh) 2015-01-21
KR20200075896A (ko) 2020-06-26
JP2022058726A (ja) 2022-04-12
ZA201406671B (en) 2016-08-31
ES2687974T3 (es) 2018-10-30
JP2018168152A (ja) 2018-11-01
CA2867265A1 (en) 2013-09-19
MX361875B (es) 2018-12-18
US11578135B2 (en) 2023-02-14
KR20210096308A (ko) 2021-08-04
EP2825553B1 (en) 2018-07-25
JP2015511962A (ja) 2015-04-23
PL2825553T3 (pl) 2018-12-31
JP7308041B2 (ja) 2023-07-13
EP2825553A1 (en) 2015-01-21
AU2017251854B2 (en) 2019-09-26
KR102494534B1 (ko) 2023-02-06
CN114133454A (zh) 2022-03-04
IL234460B (en) 2019-11-28
JP6883944B2 (ja) 2021-06-09
DK2825553T3 (en) 2018-09-24
CN104302664B (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
MX2018010776A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
MX2023003418A (es) Moleculas multiespecificas de union a antigenos y usos de estas.
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
MY195059A (en) Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
MX2021007663A (es) Molecula de union al antigeno especifico para el tejido objetivo.
MX2020004410A (es) Anticuerpos biespecificos con funciones efectoras reducidas.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
EA201791393A2 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
EP3786183A3 (en) Antigen binding constructs to cd3
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
AR079944A1 (es) Anticuerpo neutralizante de la actividad de un anticoagulante
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
EA201400447A1 (ru) АНТИТЕЛА К CD1d
WO2015112895A3 (en) Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
EA202192306A3 (ru) Полиспецифические антигенсвязывающие молекулы и их применения
EA202090303A2 (ru) Композиции антител для лечения опухолей
EA201991227A1 (ru) Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения